The pharma services sector is recovering, but unevenly. Biotech funding has returned to healthy levels, and trial starts are rebounding to previous peak levels. However, geopolitical challenges and AI disruption fears persist. At HBI 2026, a panel discussed the challenges and opportunities facing the pharma services sector.



